Clearside Biomedical, Inc. (CLSD) financial statements (2021 and earlier)

Company profile

Business Address 900 NORTH POINT PARKWAY
ALPHARETTA, GA 30005
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1723413884
Cash and cash equivalents17238935
Short-term investments  332849
Other undisclosed cash, cash equivalents, and short-term investments  0(0)(0)
Prepaid expense11210
Other current assets01000
Other undisclosed current assets  (0)00
Total current assets:1825433984
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment01110
Restricted cash and investments00000
Other noncurrent assets  000
Total noncurrent assets:12110
TOTAL ASSETS:1927444085
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4410105
Accounts payable21753
Accrued liabilities23353
Deferred revenue55
Debt1213 
Deferred rent credit  0
Deferred revenue and credits0 
Other liabilities   00
Other undisclosed current liabilities0    
Total current liabilities:101110145
Noncurrent Liabilities
Long-term debt and lease obligation15958
Long-term debt, excluding current maturities 4958
Operating lease, liability11
Liabilities, other than long-term debt  110
Deferred revenue and credits10
Deferred rent credit  1
Other undisclosed noncurrent liabilities(1)    
Total noncurrent liabilities:151068
Total liabilities:1116211913
Stockholders' equity
Stockholders' equity attributable to parent911242172
Common stock00000
Additional paid in capital265249230146137
Accumulated other comprehensive loss   (0)(0)
Accumulated deficit(256)(238)(207)(124)(65)
Total stockholders' equity:911242172
TOTAL LIABILITIES AND EQUITY:1927444085

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net 1
Gross profit:820 1
Operating expenses(26)(32)(83)(59)(26)
Other undisclosed operating income   0 
Operating loss:(18)(30)(83)(58)(25)
Nonoperating income (expense)(0)(0)0(1)(1)
Interest and debt expense(0)(1)(1)(1)(0)
Loss before gain (loss) on sale of properties:(18)(32)(84)(60)(26)
Other undisclosed net income011  
Net loss:(18)(31)(83)(60)(26)
Other undisclosed net income attributable to parent   10
Net loss available to common stockholders, diluted:(18)(31)(83)(59)(26)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(18)(31)(83)(60)(26)
Other comprehensive income (loss)   0(0)
Comprehensive loss:(18)(31)(83)(60)(26)
Other undisclosed comprehensive income, net of tax, attributable to parent   10
Comprehensive loss, net of tax, attributable to parent:(18)(31)(83)(59)(26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: